Abstract
Most oncogenes encode activators of transcription factors or transcription factors themselves. Transcription factors that are induced by growth stimuli are, in contrast to transcription factors that regulate house keeping genes, tightly regulated and only active, when a stimulus (e.g. cytokines or other growth factors) is given. Examples of such transcription factors are members of the jun, fos, myc, NFkB and STAT gene families. In cancer cells this regulation is interrupted, resulting in constitutive activities of transcription factors that are normally silent. This in turn results in the increased expression of target genes that are necessary for growth and protection from apoptosis. Since inducible transcription factors are activated by specific pathways, the identification of unusual constitutively active transcription factors also identifies the involved signal transduction pathway. Inhibitors of the components of these pathways may be effective anti-cancer agents, as they interrupt the abnormal signalling and in cancer cells. We applied this strategy for two forms of cutaneous T cell lymphomas and identified several groups of agents that may be the prototypes of new drugs to fight these diseases.
Keywords: Signal transduction, tyrosine kinase inhibitors, apoptosis inducers, skin cancer, sodium salicylate, arsenic trioxide, potassium antimonyl tartrate
Current Drug Discovery Technologies
Title: Transcription Factor Profiling Shows New Ways Towards New Treatment Options of Cutaneous T cell lymphomas
Volume: 4 Issue: 1
Author(s): Udo Dobbeling
Affiliation:
Keywords: Signal transduction, tyrosine kinase inhibitors, apoptosis inducers, skin cancer, sodium salicylate, arsenic trioxide, potassium antimonyl tartrate
Abstract: Most oncogenes encode activators of transcription factors or transcription factors themselves. Transcription factors that are induced by growth stimuli are, in contrast to transcription factors that regulate house keeping genes, tightly regulated and only active, when a stimulus (e.g. cytokines or other growth factors) is given. Examples of such transcription factors are members of the jun, fos, myc, NFkB and STAT gene families. In cancer cells this regulation is interrupted, resulting in constitutive activities of transcription factors that are normally silent. This in turn results in the increased expression of target genes that are necessary for growth and protection from apoptosis. Since inducible transcription factors are activated by specific pathways, the identification of unusual constitutively active transcription factors also identifies the involved signal transduction pathway. Inhibitors of the components of these pathways may be effective anti-cancer agents, as they interrupt the abnormal signalling and in cancer cells. We applied this strategy for two forms of cutaneous T cell lymphomas and identified several groups of agents that may be the prototypes of new drugs to fight these diseases.
Export Options
About this article
Cite this article as:
Udo Dobbeling , Transcription Factor Profiling Shows New Ways Towards New Treatment Options of Cutaneous T cell lymphomas, Current Drug Discovery Technologies 2007; 4 (1) . https://dx.doi.org/10.2174/157016307781115467
DOI https://dx.doi.org/10.2174/157016307781115467 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coordinated Expression of Pax-5 and FAK1 in Metastasis
Anti-Cancer Agents in Medicinal Chemistry Effects of Paliroden (SR57667B) and Xaliproden on Adult Brain Neurogenesis
Current Alzheimer Research Carbon Monoxide in Acute Lung Injury
Current Pharmaceutical Biotechnology Src Family Kinases as Potential Therapeutic Targets for Malignancies and Immunological Disorders
Current Medicinal Chemistry Matrix Metalloproteinases
Current Medicinal Chemistry Mechanism and Anticancer Activity of the Metabolites of an Endophytic Fungi from Eucommia ulmoides Oliv
Anti-Cancer Agents in Medicinal Chemistry Technetium Labeled Small Peptide Radiopharmaceuticals in the Identification of Lung Cancer
Current Pharmaceutical Design Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications
Current Cancer Drug Targets GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma
Current Drug Targets Exogenous Expression of WNT7A in Leukemia-Derived Cell Lines Induces Resistance to Chemotherapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Growth and Trophic Factors, pH and the Na+/H+ Exchanger in Alzheimers Disease, Other Neurodegenerative Diseases and Cancer: New Therapeutic Possibilities and Potential Dangers
Current Alzheimer Research 1-O-Octadecyl-2-O-Methylglycero-3-phosphocholine (Edelfosine) and Cancer Cell Invasion: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells
Current Stem Cell Research & Therapy Angiogenesis and Hemostasis in Hematological Neoplasias
Current Drug Targets Multiple Forms of Proteasomes and their Role in Tumor Fate
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Safety Concerns Related to Hematopoietic Stem Cell Gene Transfer Using Retroviral Vectors
Current Gene Therapy Pharmacological Strategies to Increase the Antitumor Activity of Methylating Agents
Current Medicinal Chemistry Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?
Current Pharmaceutical Biotechnology Medical Treatment of Malignancy-Associated Hypercalcemia
Current Medicinal Chemistry